Aquestive CEO sells 25,000 shares at $4.82

Aquestive Therapeutics, Inc. (AQST) reported that President and CEO Daniel Barber sold 25,000 shares of common stock on September 15, 2026 in an open-market transaction under a Rule 10b5-1 trading plan.

Available on EDGAR 09/16/2026 - 02:01 PM EDT Accepted by SEC EDGAR 09/16/2026 - 02:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. (AQST) reported that President and CEO Daniel Barber sold 25,000 shares of common stock on September 15, 2026 in an open-market transaction under a Rule 10b5-1 trading plan. The weighted average sale price was $4.8195 per share, with prices ranging from $4.78 to $4.90.

Following this transaction, Barber directly holds 652,317 shares of Aquestive Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 25,000 shares

Net Sell 1 txn

Insider Barber Daniel

Role President and CEO

Sold 25,000 shs ($120K)

Share of Position Sold 3.7%

Type	Security	Shares	Price	Value
Sale	Common Stock F1	25,000	$4.8195	$120K

Holdings After Transaction: Common Stock — 652,317 shares (Direct)

Holdings Before and After: Common Stock, 677,317 to 652,317 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The reported transaction involves sale transactions from $4.78 to $4.90 per share. The weighted average price per share was $4.8195. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 25,000 shares Weighted average sale price: $4.8195 per share Sale price range: $4.78–$4.90 per share +2 more

5 metrics

Shares sold 25,000 shares Open-market sale on September 15, 2026 by CEO Daniel Barber

Weighted average sale price $4.8195 per share Sale of 25,000 AQST shares on September 15, 2026

Sale price range $4.78–$4.90 per share Price range for the reported 25,000-share sale

Shares held after transaction 652,317 shares Direct holdings of CEO Daniel Barber after the sale

Approximate transaction value $120,488 25,000 shares sold at a weighted average of $4.8195 per share

Key Terms

Rule 10b5-1 trading plan, weighted average price per share, open-market transaction

3 terms

Rule 10b5-1 trading plan regulatory

"transaction was effected under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price per share financial

"The weighted average price per share was $4.8195."

open-market transaction financial

"Sale in open market or private transaction"

An open-market transaction is a buy or sell of a company's shares or other securities conducted on a public exchange at the current market price, rather than through a private agreement. Investors watch these trades because they change the number of shares available and can move the price immediately—similar to how a large purchase at a busy store can raise demand and affect the checkout price—so such activity can signal market sentiment and alter ownership stakes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AQST report for its CEO?

Aquestive Therapeutics reported that CEO Daniel Barber sold 25,000 shares of common stock on September 15, 2026 in an open-market transaction under a Rule 10b5-1 trading plan, at a weighted average price of $4.8195 per share.

At what prices were the AQST shares sold by the CEO on September 15, 2026?

The CEO’s reported sale of AQST shares on September 15, 2026 occurred at prices ranging from $4.78 to $4.90 per share, with a weighted average price of $4.8195 per share according to the filing footnote.

How many AQST shares does the CEO hold after the reported sale?

After the September 15, 2026 sale, CEO Daniel Barber directly holds 652,317 shares of Aquestive Therapeutics common stock, as reported in the Form 4 filing.

Was the AQST CEO’s September 2026 stock sale under a Rule 10b5-1 plan?

Yes. The Form 4 indicates the transaction was effected under a Rule 10b5-1 trading plan, meaning the sale was made pursuant to a pre-arranged trading agreement.

How many AQST shares in total were sold by the CEO in this Form 4?

The Form 4 reports a single open-market transaction in which CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics common stock, with no reported purchases or derivative exercises in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barber Daniel

(Last) (First) (Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		S		25,000	D	$4.8195(1)	652,317	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involves sale transactions from $4.78 to $4.90 per share. The weighted average price per share was $4.8195. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)